Pfizer [PFE] vs Gilead Sciences [GILD] Detailed Stock Comparison
Pfizer
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pfizer wins in 9 metrics, Gilead Sciences wins in 11 metrics, with 0 ties. Gilead Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pfizer | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.55 | 22.21 | Pfizer |
| Price-to-Book Ratio | 1.53 | 7.11 | Pfizer |
| Debt-to-Equity Ratio | 69.70 | 127.34 | Pfizer |
| PEG Ratio | 0.00 | 1.02 | Pfizer |
| EV/EBITDA | 7.54 | 11.49 | Pfizer |
| Profit Margin (TTM) | 16.84% | 21.87% | Gilead Sciences |
| Operating Margin (TTM) | 28.68% | 39.16% | Gilead Sciences |
| EBITDA Margin (TTM) | 28.68% | 39.16% | Gilead Sciences |
| Return on Equity | 12.17% | 33.40% | Gilead Sciences |
| Return on Assets (TTM) | 5.25% | 12.62% | Gilead Sciences |
| Free Cash Flow (TTM) | $9.84B | $10.31B | Gilead Sciences |
| Dividend Yield | 5.32% | 3.25% | Pfizer |
| 1-Year Return | -5.25% | 30.70% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 2.12 | 4.84 | Pfizer |
| Enterprise Value | $184.71B | $158.54B | Pfizer |
| EV/Revenue Ratio | 2.89 | 5.49 | Pfizer |
| Gross Profit Margin (TTM) | 74.22% | 78.80% | Gilead Sciences |
| Revenue per Share (TTM) | $11 | $23 | Gilead Sciences |
| Earnings per Share (Diluted) | $1.90 | $5.07 | Gilead Sciences |
| Beta (Stock Volatility) | 0.46 | 0.38 | Gilead Sciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Pfizer vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pfizer | -0.48% | 14.75% | 8.41% | 6.95% | 9.64% | 1.77% |
| Gilead Sciences | -0.53% | -0.39% | -1.91% | -0.85% | -1.19% | 20.33% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pfizer | -5.25% | -36.01% | -22.43% | -14.14% | 63.43% | 17.03% |
| Gilead Sciences | 30.70% | 71.97% | 73.18% | 9.85% | 508.48% | 830.64% |
News Based Sentiment: Pfizer vs Gilead Sciences
Pfizer
News based Sentiment: MIXED
Pfizer had a month of both positive developments – a major acquisition and strong Q2 earnings – and concerning headwinds, including looming patent expirations and increasing debt. The Metsera deal is a significant strategic move, but the overall investment story remains complex and requires careful monitoring.
Gilead Sciences
News based Sentiment: MIXED
October was a largely positive month for Gilead, with strong earnings and analyst upgrades offset by potential drug pricing pressures. The company's significant investments in R&D and manufacturing signal a commitment to long-term growth, but the Biktarvy pricing issue introduces a notable risk factor, creating a mixed overall investment narrative.
Performance & Financial Health Analysis: Pfizer vs Gilead Sciences
| Metric | PFE | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $147.88B | $139.74B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 50,010,390 | 7,201,150 |
| 90 Day Avg. Volume | 43,344,040 | 6,413,223 |
| Last Close | $27.08 | $110.56 |
| 52 Week Range | $20.92 - $30.43 | $83.10 - $121.83 |
| % from 52W High | -11.01% | -9.25% |
| All-Time High | $61.71 (Dec 20, 2021) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -56.12% | -10.38% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.02% |
| Quarterly Earnings Growth | 69.98% | 0.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.17% | 0.22% |
| Operating Margin (TTM) | 0.29% | 0.39% |
| Return on Equity (TTM) | 0.12% | 0.33% |
| Debt to Equity (MRQ) | 69.70 | 127.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.60 | $15.84 |
| Cash per Share (MRQ) | $2.33 | $4.88 |
| Operating Cash Flow (TTM) | $15.19B | $9.87B |
| Levered Free Cash Flow (TTM) | $16.02B | $8.84B |
| Dividends | ||
| Last 12-Month Dividend Yield | 5.32% | 3.25% |
| Last 12-Month Dividend | $1.27 | $3.91 |
Valuation & Enterprise Metrics Analysis: Pfizer vs Gilead Sciences
| Metric | PFE | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.55 | 22.21 |
| Forward P/E | 8.14 | 15.16 |
| PEG Ratio | 0.00 | 1.02 |
| Price to Sales (TTM) | 2.12 | 4.84 |
| Price to Book (MRQ) | 1.53 | 7.11 |
| Market Capitalization | ||
| Market Capitalization | $147.88B | $139.74B |
| Enterprise Value | $184.71B | $158.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.89 | 5.49 |
| Enterprise to EBITDA | 7.54 | 11.49 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.38 |
| Book Value per Share (MRQ) | $15.60 | $15.84 |
Financial Statements Comparison: Pfizer vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PFE | GILD |
|---|---|---|
| Revenue/Sales | $14.65B | $6.67B |
| Cost of Goods Sold | $3.78B | $1.54B |
| Gross Profit | $10.88B | $5.13B |
| Research & Development | $2.48B | $1.38B |
| Operating Income (EBIT) | $3.77B | $2.49B |
| EBITDA | $5.75B | $3.28B |
| Pre-Tax Income | $3.04B | $1.65B |
| Income Tax | $141.00M | $334.00M |
| Net Income (Profit) | $2.93B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PFE | GILD |
|---|---|---|
| Cash & Equivalents | $1.43B | $7.93B |
| Total Current Assets | $45.86B | $16.90B |
| Total Current Liabilities | $36.45B | $12.34B |
| Long-Term Debt | $56.82B | $22.15B |
| Total Shareholders Equity | $90.64B | $19.08B |
| Retained Earnings | $119.59B | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PFE | GILD |
|---|---|---|
| Operating Cash Flow | $3.91B | $1.56B |
| Capital Expenditures | $-564.00M | $-104.00M |
| Free Cash Flow | $1.77B | $1.65B |
| Debt Repayment | $-2.43B | $-1.76B |
| Common Stock Repurchase | N/A | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | PFE | GILD |
|---|---|---|
| Shares Short | 112.93M | 18.25M |
| Short Ratio | 2.85 | 2.97 |
| Short % of Float | 0.02% | 0.01% |
| Average Daily Volume (10 Day) | 50,010,390 | 7,201,150 |
| Average Daily Volume (90 Day) | 43,344,040 | 6,413,223 |
| Shares Outstanding | 5.67B | 1.25B |
| Float Shares | 5.68B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.67% | 0.91% |
Dividend Analysis & Yield Comparison: Pfizer vs Gilead Sciences
| Metric | PFE | GILD |
|---|---|---|
| Last 12-Month Dividend | $1.27 | $3.91 |
| Last 12-Month Dividend Yield | 5.32% | 3.25% |
| 3-Year Avg Annual Dividend | $1.52 | $3.30 |
| 3-Year Avg Dividend Yield | 1.27% | 0.91% |
| 3-Year Total Dividends | $4.55 | $9.91 |
| Ex-Dividend Date | Jan 24, 2025 | Sep 15, 2025 |